PHH2 Stock Overview
Paul Hartmann AG manufactures and sells medical and care products in Europe, Africa, Asia, and Oceania.
Paul Hartmann Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||€308.00|
|52 Week High||€374.00|
|52 Week Low||€308.00|
|1 Month Change||-3.45%|
|3 Month Change||-3.75%|
|1 Year Change||-15.62%|
|3 Year Change||3.36%|
|5 Year Change||-28.37%|
|Change since IPO||158.33%|
Recent News & Updates
Here's Why Paul Hartmann (FRA:PHH2) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Paul Hartmann (FRA:PHH2) Shareholders Will Want The ROCE Trajectory To Continue
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...
Is Paul Hartmann (FRA:PHH2) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
|PHH2||DE Medical Equipment||DE Market|
Return vs Industry: PHH2 exceeded the German Medical Equipment industry which returned -17.1% over the past year.
Return vs Market: PHH2 exceeded the German Market which returned -22% over the past year.
|PHH2 Average Weekly Movement||3.6%|
|Medical Equipment Industry Average Movement||6.5%|
|Market Average Movement||5.6%|
|10% most volatile stocks in DE Market||10.2%|
|10% least volatile stocks in DE Market||2.9%|
Stable Share Price: PHH2 is less volatile than 75% of German stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: PHH2's weekly volatility (4%) has been stable over the past year.
About the Company
Paul Hartmann AG manufactures and sells medical and care products in Europe, Africa, Asia, and Oceania. It offers disinfectant products for hands, surface, and instruments; cleaning, skin care, and skin antisepsis products, as well as Sterillium, a hand disinfectant; incontinence management products; and personal healthcare products, such as diagnostic devices and first aid products. The company also provides single-use and pre-surgical products, disposable surgical gloves, clothing and gowns, and disposable drapes for use in operating theatres, treatment rooms, and wards; and wound management solutions, including traditional compresses, bandages, hydro therapy products.
Paul Hartmann Fundamentals Summary
|PHH2 fundamental statistics|
Is PHH2 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PHH2 income statement (TTM)|
|Cost of Revenue||€1.03b|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||26.66|
|Net Profit Margin||4.10%|
How did PHH2 perform over the long term?See historical performance and comparison
2.6%Current Dividend Yield
Is PHH2 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PHH2?
Other financial metrics that can be useful for relative valuation.
|What is PHH2's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does PHH2's PE Ratio compare to its peers?
|PHH2 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
Price-To-Earnings vs Peers: PHH2 is good value based on its Price-To-Earnings Ratio (11.6x) compared to the peer average (32.4x).
Price to Earnings Ratio vs Industry
How does PHH2's PE Ratio compare vs other companies in the Medical Equipment Industry?
Price-To-Earnings vs Industry: PHH2 is good value based on its Price-To-Earnings Ratio (11.6x) compared to the German Medical Equipment industry average (27.9x)
Price to Earnings Ratio vs Fair Ratio
What is PHH2's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||11.6x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate PHH2's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of PHH2 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: PHH2 (€308) is trading above our estimate of fair value (€205.02)
Significantly Below Fair Value: PHH2 is trading above our estimate of fair value.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PHH2's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Paul Hartmann forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Paul Hartmann has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine Paul Hartmann's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Paul Hartmann competitive advantages and company strategy can generally be found in its financial reports archived here.
How has Paul Hartmann performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PHH2 has high quality earnings.
Growing Profit Margin: PHH2's current net profit margins (4.1%) are lower than last year (4.4%).
Past Earnings Growth Analysis
Earnings Trend: PHH2's earnings have grown by 3.7% per year over the past 5 years.
Accelerating Growth: PHH2's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PHH2 had negative earnings growth (-11.1%) over the past year, making it difficult to compare to the Medical Equipment industry average (1.3%).
Return on Equity
High ROE: PHH2's Return on Equity (8.9%) is considered low.
Discover strong past performing companies
How is Paul Hartmann's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: PHH2's short term assets (€989.5M) exceed its short term liabilities (€456.2M).
Long Term Liabilities: PHH2's short term assets (€989.5M) exceed its long term liabilities (€275.9M).
Debt to Equity History and Analysis
Debt Level: PHH2 has more cash than its total debt.
Reducing Debt: PHH2's debt to equity ratio has reduced from 2.7% to 1% over the past 5 years.
Debt Coverage: PHH2's debt is well covered by operating cash flow (1229.4%).
Interest Coverage: PHH2 earns more interest than it pays, so coverage of interest payments is not a concern.
Discover healthy companies
What is Paul Hartmann current dividend yield, its reliability and sustainability?
Dividend Score 4/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: PHH2's dividend (2.6%) is higher than the bottom 25% of dividend payers in the German market (1.47%).
High Dividend: PHH2's dividend (2.6%) is low compared to the top 25% of dividend payers in the German market (4.53%).
Stability and Growth of Payments
Stable Dividend: PHH2's dividends per share have been stable in the past 10 years.
Growing Dividend: PHH2's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (30%), PHH2's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its high cash payout ratio (2123.6%), PHH2's dividend payments are not well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Britta Fuenfstueck (42 yo)
Ms. Britta Fuenfstueck has been Chief Executive Officer at Paul Hartmann AG since January 1, 2019 and its Management Board Member since January 1, 2019 and has been its Chairwoman of Management Board since...
Experienced Management: PHH2's management team is seasoned and experienced (6.2 years average tenure).
Experienced Board: PHH2's board of directors are seasoned and experienced ( 14.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Paul Hartmann AG's employee growth, exchange listings and data sources
- Name: Paul Hartmann AG
- Ticker: PHH2
- Exchange: DB
- Founded: 1818
- Industry: Health Care Supplies
- Sector: Healthcare
- Implied Market Cap: €1.094b
- Shares outstanding: 3.55m
- Website: https://hartmann.info
Number of Employees
- Paul Hartmann AG
- Paul-Hartmann-Straße 12
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/26 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.